Yonghuai Feng

Dr. Yonghuai Feng

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
SZShasha zou
Shasha zou
BLBo Liu
Bo Liu
YFYonghuai Feng
Yonghuai Feng
Hematological malignancies (HM) are common malignant tumors with high morbidity and mortality rates, and are malignant diseases that seriously affect human health, with chemotherapy prone to recurrence and toxic side effects. Therefore, the development of precise, effective, and safe targeted therapeutic agents has become a hotspot in the current research of antitumor technology. More and more studies have shown that the interaction of C–C chemokine ligand 17 (CCL17) and C–C chemokine ligand 22 (CCL22) with the receptor C–C chemokine receptor type 4 (CCR4) promotes the immune escape of tumors and is closely related to the occurrence, development, and prognosis of hematological tumors. In this regard, we present a review on the expression and role of the CCL17/CCL22-CCR4 axis in HM, including lymphoma, leukemia, and multiple myeloma, with the aim of providing latest ideas and directions for the diagnosis and treatment of HM. In addition, we discuss the role and related mechanisms of HM therapeutic agents targeting the CCL17/CCL22-CCR4 axis and the potential of humanized anti-CCR4 antibodies for the treatment of HM.

22 December 2022 in Ibrain
Verified
Journal Article
Open access
XLXiaoli Lv
Xiaoli Lv
YMYingwei Mao
Yingwei Mao
SCSong Cao
Song Cao
YFYonghuai Feng
Yonghuai Feng
Chemotherapy is one of the main treatments for hematologic malignancies. However, chemotherapy‐induced peripheral neuropathy (CIPN) is one of the most common long‐term toxic reactions in chemotherapy, and the occurrence of CIPN affects patients’ quality of life and can cause interruption of chemotherapy in severe cases, thus reducing the efficacy of chemotherapy. We currently summarize the existing CIPN animal models, including the characteristics of several common animal models such as bortezomib‐induced peripheral neuropathy, vincristine‐induced peripheral neuropathy, and oxaliplatin‐induced peripheral neuropathy. It was found that CIPN may lead to behavioral, histopathological, and neurophysiological changes inducing peripheral neuropathy. However, the mechanism of CIPN has not been fully elucidated, especially the prevention and treatment protocols need to be improved. Therefore, this review article summarizes the progress of research on CIPN animal models and the possible mechanisms and treatment of CIPN.

6 September 2023 in Ibrain
Verified
Journal Article
Open access
DWDan Wen
Dan Wen
SCSong Cao
Song Cao
YFYonghuai Feng
Yonghuai Feng
The incidence of multiple myeloma (MM) is increasing year by year, requiring chemotherapy drugs to control the condition. With the advent of new proteasome inhibitors, immunomodulators, and monoclonal antibodies, the prognosis of patients has improved significantly. However, peripheral neuropathy caused by drugs limits the dose and duration of treatment, which seriously affects patients' quality of life and treatment outcome. Although the neuropathies induced by chemotherapy drugs have attracted much attention, their mechanism and effective prevention and treatment measures are not clear. Therefore, how to alleviate peripheral neuropathy caused by drugs for treatment of MM is a key issue in improving patients' quality of life and prolonging their survival time, which have some clinical value. In this paper, we review the current research on the pathogenesis, pharmacological and nonpharmacological treatment, and prevention, which expects to present instruction for peripheral neuropathy after treatment of MM.

1 December 2020
Verified
Journal Article
Closed access
CYCheng-Feng Yi
Cheng-Feng Yi
YCYu-Xi Cai
Yu-Xi Cai
YQYun-Jie Qiu
Yun-Jie Qiu
YZYue Zhao
Yue Zhao
LWLiu-Song Wu
Liu-Song Wu
YFYonghuai Feng
Yonghuai Feng

14 July 2024
Verified
Journal Article
Open access
ZXZ F Xiao
Z F Xiao
SZS S Zou
S S Zou
CYC F Yi
C F Yi
YZY Zhao
Y Zhao
LWL S Wu
L S Wu
YFYonghuai Feng
Yonghuai Feng
Objective: To study the expressions of C-C class chemokine 17 (CCL17), C-C class chemokine 22 (CCL22), and C-C chemokine receptor 4 (CCR4) in newly diagnosed multiple myeloma (NDMM) for analyzing their correlations with clinical features and to preliminarily explore their roles in the development of NDMM. Methods: The study included 40 patients with NDMM and 20 healthy volunteers from the Department of Hematology of the Affiliated Hospital of Zunyi Medical University from July 2020 to December 2022. Peripheral blood, bone marrow, and bone marrow biopsy tissue samples were collected from the two groups. The expression levels of CCL17, CCL22, and CCR4 in patients with NDMM were analyzed using real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR), enzyme-linked immunosorbent assay (ELISA), and immunohistochemistry. The mRNA expression levels of CCL17, CCL22, and CCR4 in the bone marrow mononuclear cell (BMMNC) of patients with NDMM were analyzed to assess their correlations with clinical indicators. Results: The mRNA expression levels of CCL17, CCL22, and CCR4 in BMMNC were higher in patients with NDMM than in controls (all P<0.05). The protein expression levels of CCL17 and CCL22 in peripheral blood supernatants and bone marrow supernatants were higher in patients with NDMM than in controls (all P<0.05). The expression levels of CCL17, CCL22, and CCR4 in bone marrow biopsy tissues were higher in patients with NDMM than in controls (all P<0.05). The mRNA expression level of CCL17 was increased in NDMM patients with combined anemia, bone damage, renal damage, and M protein level ≥30 g/L (all P<0.05). The mRNA expression level of CCL22 was increased in NDMM patients with combined anemia, bone damage, and renal damage (all P<0.05). The mRNA expression level of CCR4 was increased in NDMM patients with combined anemia and renal damage (all P<0.05) . Conclusion: CCL17, CCL22, and CCR4 were highly expressed in clinical samples from patients with NDMM compared to those from controls, and they may be involved in the occurrence and development of NDMM.

1 April 2026 in The Korean Journal of Pain
Verified
Journal Article
Open access
PDF file
LGLong Gu
Long Gu
XLXiaoli Lv
Xiaoli Lv
SCSong Cao
Song Cao
YFYonghuai Feng
Yonghuai Feng
Long Gu, Xiaoli Lv, Song Cao, and Yonghuai Feng. Korean J Pain 2026;39:246-59. https://doi.org/10.3344/kjp.25341